stoxline Quote Chart Rank Option Currency Glossary
  
Reunion Neuroscience Inc. (REUN)
1.12  -0.01 (-0.89%)    07-31 15:59
Open: 1.13
High: 1.13
Volume: 19,003
  
Pre. Close: 1.13
Low: 1.11
Market Cap: 13(M)
Technical analysis
2023-09-01 4:49:31 PM
Short term     
Mid term     
Targets 6-month :  1.32 1-year :  1.34
Resists First :  1.13 Second :  1.14
Pivot price 1.11
Supports First :  1.1 Second :  0.91
MAs MA(5) :  1.12 MA(20) :  1.11
MA(100) :  0.9 MA(250) :  1.45
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  50 D(3) :  41.6
RSI RSI(14): 60.8
52-week High :  7.61 Low :  0.63
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ REUN ] has closed below upper band by 39.3%. Bollinger Bands are 90.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.12 - 1.13 1.13 - 1.13
Low: 1.1 - 1.11 1.11 - 1.12
Close: 1.11 - 1.12 1.12 - 1.13
Company Description

Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.

Headline News

Tue, 01 Aug 2023
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement - GlobeNewswire

Fri, 02 Jun 2023
Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions - MicroCap Daily

Thu, 01 Jun 2023
Reunion Neuroscience to be acquired by MPM BioImpact in US$13.1M deal - Mugglehead

Thu, 01 Jun 2023
Reunion Neuroscience Announces US$13.1 Million Take-Private - GlobeNewswire

Wed, 26 Apr 2023
Reunion Neuroscience struggles to maintain Nasdaq listing requirements - Mugglehead

Tue, 14 Mar 2023
Reunion Neuroscience Files Lawsuit Against Mindset Pharma - Psychedelic Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 12 (M)
Shares Float 3 (M)
Held by Insiders 34.3 (%)
Held by Institutions 50.6 (%)
Shares Short 115 (K)
Shares Short P.Month 179 (K)
Stock Financials
EPS -2.51
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.82
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -26.5 %
Return on Equity (ttm) -86.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.2
Qtrly Earnings Growth 0 %
Operating Cash Flow -28 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio -0.45
PEG Ratio 0
Price to Book value 0.61
Price to Sales 0
Price to Cash Flow -0.48
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android